설명
Liver disease including NAFLD and NASH outcomes comparing EPA and DHA supplementation show different efficacy profiles in hepatoprotection.
Figure 30
Source Paper
Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete against Each Other?Cite This Figure
![Figure 30: Liver disease including NAFLD and NASH outcomes comparing EPA and DHA supplementation show different efficacy profiles in hepatoprotection.]() > Source: Anandita Pal et al. "Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete ." *Nutrients*, 2020. PMID: [33276463](https://pubmed.ncbi.nlm.nih.gov/33276463/)
<figure> <img src="" alt="Liver disease including NAFLD and NASH outcomes comparing EPA and DHA supplementation show different efficacy profiles in hepatoprotection." /> <figcaption>Figure 30. Liver disease including NAFLD and NASH outcomes comparing EPA and DHA supplementation show different efficacy profiles in hepatoprotection.<br> Source: Anandita Pal et al. "Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete ." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33276463/">33276463</a></figcaption> </figure>